Crawford S W, Petersen F B
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Am Rev Respir Dis. 1992 Mar;145(3):510-4. doi: 10.1164/ajrccm/145.3.510.
Respiratory failure was measured as the institution of assisted mechanical ventilation for hypoxemic (oxygenation) or hypercarbic (ventilatory) failure after marrow transplantation. There were 348 (23%) marrow recipients who required mechanical ventilation for an average of 8 days (median, 5; range, 1 to 45). The average onset of mechanical ventilation was 39 days (median, 22; range, 0 to 172) after transplantation. Factors previously found to be associated with mechanical ventilation were tested in a Cox proportional hazards model. Older age, active malignancy at time of transplantation, and donor-recipient marrow HLA-non-identity were independent risks for assisted mechanical ventilation after marrow transplantation. Twenty-one percent (n = 72) of the marrow recipients receiving assisted mechanical ventilation for respiratory failure were extubated. Four percent (n = 15) were discharged from the hospital, and 3% (n = 10) survived 6 months after transplantation. All of these survivors were physically functional. Three had mild chronic respiratory symptoms and restrictive or obstructive airflow defects 1 yr after transplantation. Respiratory failure requiring assisted mechanical ventilatory support occurs in 23% of marrow recipients and is associated with functional survival at 6 months in 3%. Older age, active malignancy at time of transplantation, and donor-recipient marrow HLA-non-identity are risk factors for subsequent respiratory failure. In view of the poor prognosis associated with respiratory failure, these factors should be considered when counseling patients and families regarding this mode of treatment.
呼吸衰竭的衡量标准为骨髓移植后因低氧血症(氧合)或高碳酸血症(通气)衰竭而实施的辅助机械通气。共有348名(23%)骨髓接受者需要机械通气,平均时长为8天(中位数为5天;范围为1至45天)。机械通气的平均起始时间为移植后39天(中位数为22天;范围为0至172天)。在Cox比例风险模型中对先前发现的与机械通气相关的因素进行了测试。年龄较大、移植时存在活动性恶性肿瘤以及供受者骨髓HLA不匹配是骨髓移植后辅助机械通气的独立风险因素。接受呼吸衰竭辅助机械通气的骨髓接受者中有21%(n = 72)拔管。4%(n = 15)出院,3%(n = 10)在移植后存活6个月。所有这些幸存者身体功能良好。3人在移植后1年有轻度慢性呼吸道症状以及限制性或阻塞性气流缺陷。23%的骨髓接受者发生需要辅助机械通气支持的呼吸衰竭,3%的患者在6个月时功能存活。年龄较大、移植时存在活动性恶性肿瘤以及供受者骨髓HLA不匹配是后续呼吸衰竭的风险因素。鉴于与呼吸衰竭相关的预后较差,在就这种治疗方式向患者及其家属提供咨询时应考虑这些因素。